SCHEMBL353853

SCHEMBL353853

Cc1cc(C(=O)NC2CCc3cc(C(=O)NO)ccc3C2)c(C)n1Cc1cccs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.50
NPC1 O15118 9/20 0.50
MAPT P10636 4/20 0.49
ALDH1A1 P00352 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KLKB1 P03952 1/20 0.47
KLK1 P06870 1/20 0.47
TSHR P16473 5/20 0.43
TP53 P04637 4/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 7/20 0.42
LMNA P02545 6/20 0.42
NR2F2 P24468 2/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HDAC8 Q9BY41 5/20 0.41
HDAC6 Q9UBN7 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KLF5 Q13887 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246878 0.73 NPC1 (0.63) RAB9ANPC1LMNAHDAC8HDAC6
SCHEMBL10246876 0.72 PLK1 (0.51) RAB9ANPC1MAPTTP53SMN1; SMN2
SCHEMBL10247194 0.72 TRPV4 (0.59) MAPTALDH1A1KMT2AMAPK1
SCHEMBL10246881 0.71 HDAC8 (0.52) HDAC8HDAC6
SCHEMBL10247061 0.70 NPC1 (0.51) RAB9ANPC1MAPTALDH1A1L3MBTL1
SCHEMBL10247274 0.70 HDAC8 (0.54) MEN1KMT2AHDAC8HDAC6
SCHEMBL356788 0.69 HDAC6 (0.60) RAB9ANPC1HDAC8HDAC6
SCHEMBL12210529 0.69 HDAC6 (0.62) RAB9ANPC1MAPTALDH1A1L3MBTL1
SCHEMBL10246883 0.68 HDAC8 (0.65) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL4114205 0.68 RAB9A (0.81) RAB9ANPC1MAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 RAB9A 1801/4885NPC1 2866/4885MAPT 1965/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 RAB9A 1003/4885NPC1 2958/4885MAPT 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.